专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明申请

US20110256190A1 Modified release compositions comprising tacrolimus 有权
公开(公告)号：US20110256190A1
公开(公告)日：2011-10-20
申请号：US13167334
申请日：2011-06-23
申请人： Per HOLM , Tomas Norling
发明人： Per HOLM , Tomas Norling
IPC分类号： A61K31/436 , A61P37/06 , A61K9/14
CPC分类号： A61K31/436 , A61K9/0053 , A61K9/10 , A61K9/1611 , A61K9/1617 , A61K9/1623 , A61K9/1641 , A61K9/1652 , A61K9/2009 , A61K9/2013 , A61K9/2018 , A61K9/2027 , A61K9/2031 , A61K9/2054 , A61K9/2077 , A61K9/2095 , A61K9/2846 , A61K9/2893 , A61K31/00 , A61K31/439 , A61K31/4745 , Y10S514/885
摘要： A modified release composition comprising tacrolimus releases less than 20% w/w of the active ingredient within 0.5 hours when subjected to an in vitro dissolution test using USP Paddle method and using 0.1 N HCl as dissolution medium and has increased bioavailability by effectively reducing or even avoiding the effects of CYP3A4 metabolism. The modified composition may be coated with an enteric coating; and/or may comprise a solid dispersion or a solid solution of tacrolimus in a hydrophilic or water-miscible vehicle and one or more modifying release agents; and/or may comprise a solid dispersion or a solid solution of tacrolimus in an amphiphilic or hydrophobic vehicle and optionally one or more modifying release agents.

12. 发明申请

US20100323008A1 SOLID DOSAGE FORM COMPRISING A FIBRATE 有权
标题翻译：固体剂型包含纤维素
公开(公告)号：US20100323008A1
公开(公告)日：2010-12-23
申请号：US12642563
申请日：2009-12-18
申请人： Per Holm , Tomas Norling
发明人： Per Holm , Tomas Norling
IPC分类号： A61K9/32 , A61K31/216 , A61P3/00
CPC分类号： A61K9/20 , A61K9/2013 , A61K9/2018 , A61K31/192 , A61K31/195 , A61K31/216 , A61K31/22 , A61K31/40 , A61K45/06 , A61K2300/00
摘要： The invention provides stable, solid dosage forms and pharmaceutical compositions in particulate form comprising a fibrate, for example fenofibrate, dissolved in an non-aqueous vehicle in order to ensure improved bioavailability of the active ingredient upon oral administration relative to known fibrate formulations.
摘要翻译：本发明提供稳定的固体剂型和药物组合物，其包含溶解在非水载体中的贝特类，例如非诺贝特，以确保相对于已知的贝特类制剂口服给药时活性成分的生物利用度得到改善。

13. 发明申请

US20070105912A1 Pharmaceutical compositions comprising lercanidipine 审中-公开
标题翻译：包含氯卡地平的药物组合物
公开(公告)号：US20070105912A1
公开(公告)日：2007-05-10
申请号：US10581128
申请日：2004-12-01
申请人： Per Holm , Tomas Norling
发明人： Per Holm , Tomas Norling
IPC分类号： A61K31/455
CPC分类号： A61K31/44 , A61K9/1611 , A61K9/1617 , A61K9/1623 , A61K9/1641 , A61K9/1652 , A61K9/2018 , A61K9/2031 , A61K9/2054 , A61K9/4858 , A61K31/4418
摘要： A controlled release pharmaceutical composition comprising lercanidipine dissolved or dispersed in a solid vehicle at ambient temperature, thus forming a solid dispersion, achieves delayed release of lercanidipine over an extended period of time, reduced food effect and increased bioavailability compared to commercially available lercanidipine containing products.
摘要翻译：一种控释药物组合物，其包含在环境温度下溶解或分散在固体载体中的氯卡地平，从而形成固体分散体，与市售的含有乐卡西地平的产品相比，在延长的时间段内实现延迟释放莱卡西平，降低的食物效应和增加的生物利用度。

14. 发明授权

US5955502A Use of fatty acid esters as bioadhesive substances 失效
标题翻译：使用脂肪酸酯作为生物粘附物质
公开(公告)号：US5955502A
公开(公告)日：1999-09-21
申请号：US829496
申请日：1997-03-27
申请人： Jens Hansen , Lise Sylvest Nielsen , Tomas Norling
发明人： Jens Hansen , Lise Sylvest Nielsen , Tomas Norling
IPC分类号： A61K9/00 , A61K9/127 , A61K9/50 , A61K47/14 , B82B1/00 , A61K38/00 , A61K39/395
CPC分类号： A61K9/0014 , A61K47/14 , A61K9/1274 , A61K9/5015 , A61K9/5078
摘要： Use of fatty acid esters as bioadhesive substances. The fatty acid esters have molecular weights below about 1000 dalton and the fatty acid component of the fatty acid ester is a saturated or unsaturated fatty acid having a total number of carbon atoms of from C.sub.8 to C.sub.22. Particularly suitable fatty acid esters for use according to the invention are fatty acid esters which are selected from the group consisting of fatty acid esters of polyhydric alcohols, fatty acid esters of hydroxycarboxylic acids, fatty acid esters of monosaccharides, fatty acid esters of glycerylphosphate derivatives, fatty acid esters of glycerylsulfate derivative, and mixtures thereof. Excellent bioadhesive properties have been observed for fatty acid esters are glyceryl monooleate, glyceryl monolinoleate or glyceryl monolinolenate.Methods are described for administering an active or protective substance to undamaged or damaged skin or mucosa of an animal such as a human by combining the active or protective substance with a bioadhesive fatty acid ester. The mucosa may be the oral, aural, nasal, lung, gastrointestinal, vaginal, or rectal mucosa. The administration may also be to body cavities such as the oral cavity, e.g. via buccal administration.
摘要翻译：使用脂肪酸酯作为生物粘附物质。脂肪酸酯的分子量低于约1000道尔顿，脂肪酸酯的脂肪酸组分是碳原子数为C8〜C22的饱和或不饱和脂肪酸。根据本发明使用的特别合适的脂肪酸酯是选自多元醇的脂肪酸酯，羟基羧酸的脂肪酸酯，单糖的脂肪酸酯，磷酸甘油酯衍生物的脂肪酸酯，甘油硫酸酯衍生物的脂肪酸酯及其混合物。已经观察到对于脂肪酸酯具有优异的生物粘合性质，是单油酸甘油酯，单烯醇甘油酯或甘油单苯三酸盐。描述了通过将活性或保护性物质与生物粘附性脂肪酸酯组合来将活性或保护性物质施用于动物如人的未损伤或损伤的皮肤或粘膜的方法。粘膜可以是口服，听觉，鼻，肺，胃肠道，阴道或直肠粘膜。给药也可以是体腔，例如口腔，例如。通过口腔管理。

15. 发明授权

US08582444B2 Method for detecting hardware faults by determining a ratio of released connections 有权
标题翻译：通过确定释放连接的比例来检测硬件故障的方法
公开(公告)号：US08582444B2
公开(公告)日：2013-11-12
申请号：US13058069
申请日：2008-08-28
申请人： Oscar Zee , Tomas Norling
发明人： Oscar Zee , Tomas Norling
IPC分类号： G01R31/08
CPC分类号： H04W24/06 , H04L41/5035
摘要： The present invention provides a method of detecting a faulty network element in a network, the network comprising at least a plurality of first network elements having a first network element type, and at least a plurality of second network elements having a second network element type. The method comprises the steps of: a) selecting one of the plurality of first network elements and one of the plurality of second network elements; b) attempting to set up a connection between said selected first network element and said selected second network element; c) repeating steps a) and b) for further selected first and second network elements; d) for each of the plurality of first network elements and for each of the plurality of second network elements, counting a number of connections that are released as the result of a fault; and e) for a particular one of the first or second network elements, on the basis of said number of connections that are released in said particular network element as a result of a fault, determining whether said particular network element is faulty.
摘要翻译：本发明提供一种检测网络中故障网元的方法，所述网络包括至少多个具有第一网元类型的第一网元和至少具有第二网元类型的第二网元。该方法包括以下步骤：a）选择多个第一网元中的一个和多个第二网元中的一个; b）尝试在所述选择的第一网络元件和所选择的第二网络元件之间建立连接; c）对进一步选择的第一和第二网络元件重复步骤a）和b）; d）对于所述多个第一网络元件中的每一个以及对于所述多个第二网络元件中的每一个，计数由于故障而被释放的连接数; 以及e）对于所述第一或第二网络元件中的特定的一个，基于作为故障的结果在所述特定网络元件中释放的所述连接数量，确定所述特定网络元件是否有故障。

16. 发明申请

US20120195965A1 SOLID DOSAGE FORM COMPRISING A FIBRATE 有权
标题翻译：固体剂型包含纤维素
公开(公告)号：US20120195965A1
公开(公告)日：2012-08-02
申请号：US13315030
申请日：2011-12-08
申请人： Per HOLM , Tomas NORLING
发明人： Per HOLM , Tomas NORLING
IPC分类号： A61K31/216 , B29B9/00 , A61P7/00 , A61K9/14 , A61K9/20
CPC分类号： A61K9/20 , A61K9/2013 , A61K9/2018 , A61K31/192 , A61K31/195 , A61K31/216 , A61K31/22 , A61K31/40 , A61K45/06 , A61K2300/00
摘要： The invention provides stable, solid dosage forms and pharmaceutical compositions in particulate form comprising a fibrate, for example fenofibrate, dissolved in an non-aqueous vehicle in order to ensure improved bioavailability of the active ingredient upon oral administration relative to known fibrate formulations.
摘要翻译：本发明提供稳定的固体剂型和药物组合物，其包含溶解在非水载体中的贝特类，例如非诺贝特，以确保相对于已知的贝特类制剂，口服给药后活性成分的生物利用度得到改善。

17. 发明授权

US08124125B2 Solid dosage form comprising a fibrate 有权
标题翻译：包含贝特类的固体剂型
公开(公告)号：US08124125B2
公开(公告)日：2012-02-28
申请号：US12642563
申请日：2009-12-18
申请人： Per Holm , Tomas Norling
发明人： Per Holm , Tomas Norling
IPC分类号： A61K9/20
CPC分类号： A61K9/20 , A61K9/2013 , A61K9/2018 , A61K31/192 , A61K31/195 , A61K31/216 , A61K31/22 , A61K31/40 , A61K45/06 , A61K2300/00
摘要： The invention provides stable, solid dosage forms and pharmaceutical compositions in particulate form comprising a fibrate, for example fenofibrate, dissolved in an non-aqueous vehicle in order to ensure improved bioavailability of the active ingredient upon oral administration relative to known fibrate formulations.
摘要翻译：本发明提供稳定的固体剂型和药物组合物，其包含溶解在非水载体中的贝特类，例如非诺贝特，以确保相对于已知的贝特类制剂，口服给药后活性成分的生物利用度得到改善。

18. 发明申请

US20120029009A1 Tacrolimus For Improved Treatment Of Transplant Patients 有权
标题翻译：他克莫司用于改善移植患者的治疗
公开(公告)号：US20120029009A1
公开(公告)日：2012-02-02
申请号：US13167420
申请日：2011-06-23
申请人： Robert D. Gordon , Per Holm , Anne-Marie Lademann , Tomas Norling
发明人： Robert D. Gordon , Per Holm , Anne-Marie Lademann , Tomas Norling
IPC分类号： A61K31/436 , A61P37/06
CPC分类号： A61K31/436 , A61K9/0053 , A61K9/1617 , A61K9/1641 , A61K9/1652 , A61K9/2013 , A61K9/2027 , A61K9/2031 , A61K9/2054 , A61K9/2077 , A61K9/284 , A61K9/2846 , A61K9/4891 , A61K47/10 , Y10S514/885
摘要： An extended release oral dosage form comprising as active substance tacrolimus or a pharmaceutically active analogue thereof for a once daily immunosuppressive treatment of a patient in need thereof, preferable a kidney or liver transplant patient. The dosage form releases the active substance over an extended period of time. It also provides improved pharmacokinetic parameters due to an extended and constant in vivo release including substantial decreased peak concentrations, despite increased bioavailability, substantial extended times for maximal concentration, and higher minimal concentrations when compared with conventional immediate release dosage forms and a recent modified release tacrolimus dosage form.
摘要翻译：包括作为活性物质他克莫司或其药学活性类似物的延长释放口服剂型，每天一次免疫抑制治疗有需要的患者，优选肾或肝移植患者。剂型长时间释放活性物质。它还提供改善的药物动力学参数，由于延长的和恒定的体内释放，包括显着降低的峰浓度，尽管与常规立即释放剂型和最近的改进释放他克莫司相比，尽管生物利用度增加，最大浓度的显着延长时间和更高的最小浓度剂型

19. 发明申请

US20110251232A1 Modified release compositions comprising tacrolimus 有权
公开(公告)号：US20110251232A1
公开(公告)日：2011-10-13
申请号：US13167281
申请日：2011-06-23
申请人： Per HOLM , Tomas NORLING
发明人： Per HOLM , Tomas NORLING
IPC分类号： A61K31/439 , A61P37/06
CPC分类号： A61K31/436 , A61K9/0053 , A61K9/10 , A61K9/1611 , A61K9/1617 , A61K9/1623 , A61K9/1641 , A61K9/1652 , A61K9/2009 , A61K9/2013 , A61K9/2018 , A61K9/2027 , A61K9/2031 , A61K9/2054 , A61K9/2077 , A61K9/2095 , A61K9/2846 , A61K9/2893 , A61K31/00 , A61K31/439 , A61K31/4745 , Y10S514/885
摘要： A modified release composition comprising tacrolimus releases less than 20% w/w of the active ingredient within 0.5 hours when subjected to an in vitro dissolution test using USP Paddle method and using 0.1 N HCl as dissolution medium and has increased bioavailability by effectively reducing or even avoiding the effects of CYP3A4 metabolism. The modified composition may be coated with an enteric coating; and/or may comprise a solid dispersion or a solid solution of tacrolimus in a hydrophilic or water-miscible vehicle and one or more modifying release agents; and/or may comprise a solid dispersion or a solid solution of tacrolimus in an amphiphilic or hydrophobic vehicle and optionally one or more modifying release agents.

20. 发明申请

US20110250277A1 Modified release compositions comprising tacrolimus 有权
公开(公告)号：US20110250277A1
公开(公告)日：2011-10-13
申请号：US13167160
申请日：2011-06-23
申请人： Per Holm , Tomas Norling
发明人： Per Holm , Tomas Norling
IPC分类号： A61K9/14 , A61P37/06 , A61K31/436
CPC分类号： A61K31/436 , A61K9/0053 , A61K9/10 , A61K9/1611 , A61K9/1617 , A61K9/1623 , A61K9/1641 , A61K9/1652 , A61K9/2009 , A61K9/2013 , A61K9/2018 , A61K9/2027 , A61K9/2031 , A61K9/2054 , A61K9/2077 , A61K9/2095 , A61K9/2846 , A61K9/2893 , A61K31/00 , A61K31/439 , A61K31/4745 , Y10S514/885
摘要： A modified release composition comprising tacrolimus releases less than 20% w/w of the active ingredient within 0.5 hours when subjected to an in vitro dissolution test using USP Paddle method and using 0.1 N HCl as dissolution medium and has increased bioavailability by effectively reducing or even avoiding the effects of CYP3A4 metabolism. The modified composition may be coated with an enteric coating; and/or may comprise a solid dispersion or a solid solution of tacrolimus in a hydrophilic or water-miscible vehicle and one or more modifying release agents; and/or may comprise a solid dispersion or a solid solution of tacrolimus in an amphiphilic or hydrophobic vehicle and optionally one or more modifying release agents.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式